ABBVAbbVie
$276.40+27% 1Y
$276.40
$197.3852 weeks$276.40
Latest close: a new 52-week highOct 9, 2026what changed →
ABBV in its own filings
Nothing in ABBV's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
315
Events found in the filings · across 1,515 filings · the record starts in 2012
- Hard flags
- none
Hard flags
- Most recent filing
- Oct 5, 2026
Most recent filing · Form 8-K
- Record starts
- Jul 2, 2012
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Jan 6, 2027
- Change in certifying accountant2 occurrences
- 2013-03-19
- Security removed from listing or deregistered5 occurrences · usually a matured note or preferred class, not the common shares
- 2024-06-03
- Material impairment2 occurrences
- 2025-01-10
- SEC comment-letter activity38 occurrences
- 2022-10-20
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 5, 2026Guidance Including the Impact of Acquired IPR&D and Milestones Expense.Earnings release · press release
- Sep 3, 2026AbbVie Completes Acquisition of Apogee Therapeutics.Regulation FD disclosure · press release
- Aug 18, 2026On August 18, 2026, AbbVie Inc. (“AbbVie”) completed its previously announced underwritten public offering (the “Notes Offering”) of $500,000,000 aggregate principal amount of its senior floating rate notes due 2028 (the “Floating Rate Notes”), $1,000,000,000 aggregate principal amount of its 4.500% senior notes due …Other event · Form 8-K
- Aug 5, 2026On August 4, 2026, AbbVie Inc. (“AbbVie”) entered into an underwriting agreement (the “Underwriting Agreement”) with Morgan Stanley & Co. LLC, BofA Securities, Inc., J.P. Morgan Securities LLC and SG Americas Securities, LLC, acting for themselves and as representatives of the several underwriters named in Schedule II …Other event · Form 8-K
- Jul 31, 2026AbbVie Reports Second-Quarter 2026 Financial Results.Earnings release · press release
- Jul 6, 2026Guidance Including the Impact of Acquired IPR&D and Milestones Expense.Earnings release · press release
- Apr 29, 2026AbbVie Reports First-Quarter 2026 Financial Results.Earnings release · press release
- Apr 3, 2026Guidance Including the Impact of Acquired IPR&D and Milestones Expense.Earnings release · press release
- Mar 4, 2026On March 4, 2026, AbbVie Inc. (“AbbVie”) completed its previously announced underwritten public offering (the “Notes Offering”) of $750,000,000 aggregate principal amount of its senior floating rate notes due 2028 (the “Floating Rate Notes”), $1,500,000,000 aggregate principal amount of its 3.775% senior notes due …Other event · Form 8-K
- Feb 26, 2026On February 24, 2026, AbbVie Inc. (“AbbVie”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, BofA Securities, Inc., Morgan Stanley & Co. LLC and Wells Fargo Securities, LLC, acting for themselves and as representatives of the several underwriters named in Schedule …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
Drug Manufacturers, General
The closest names by size in the same industry